BI & PXS Nash drug still has the potential to be the "Best in Class" Nash drug and this would be significant . Most advanced drug in NASH area is now Intercept´s (ICPT) Ocaliva but the drug has horrible side effects and weak efficacy another potential competitor is Gilead but their drug failed in late stage trials .There are other 2 companies (Genfit & Madrigal) who will report Phase 3 data in short term but i think these drugs will fail too .
Intercept, Intercepted Before The NASH Goal Line
https://seekingalpha.com/article/4276067-intercept-intercepted-nash-goal-line
BI & PXS Nash drug still has the potential to be the "Best in...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
